Catalog No.
PVV11802
Species reactivity
Human papillomavirus type 18
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant HPV18 L1/Major capsid protein L1.
Tested applications
ELISA: 1:4000-1:8000, WB: 1:1000-1:4000
Target
Major capsid protein L1, L1, HPV18
Purification
Purified by antigen affinity column.
Accession
P06794, NP_040317.1
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Human Papillomavirus and Thyroid Eye Disease., PMID:40272832
[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350
A Novel Association Between Human Papillomavirus and Thyroid Eye Disease., PMID:38746201
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512
Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545
Designing of DNA Vaccine Based on a Secretory Form of Major Capsid Protein of Human Papillomavirus Type 18., PMID:34664812
The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits., PMID:34189649
Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency., PMID:33636291
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433
Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies., PMID:33493568
Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485
Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates., PMID:32986347
Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963
Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry., PMID:32067760
Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women., PMID:30755156
Sex differences in HPV immunity among adults without cancer., PMID:30650013
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity., PMID:30560935
Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid., PMID:30287156
Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies., PMID:30115088
L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine., PMID:29984037
A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice., PMID:29854852
Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types., PMID:28968993
Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies., PMID:28855937
Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine., PMID:28736197
HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL., PMID:28480334
Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies., PMID:28158224
The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies., PMID:28004837
Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran., PMID:27858157
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles., PMID:27147749
Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes., PMID:27113165
Observations on the expression of human papillomavirus major capsid protein in HeLa cells., PMID:26064080
Seroprevalence of 10 human papillomavirus types in the general rural population of Anyang, China: a cross-sectional study., PMID:25999521
Development of chimeric candidate vaccine against HPV18: a proof of concept., PMID:25929429
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types., PMID:25790098
HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men., PMID:25668644
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins., PMID:25203446
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines., PMID:23722024
Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation., PMID:23536912
Detection of HPV E7 oncoviral protein in cervical lesions by a new antibody., PMID:22935825
Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies., PMID:22761294
Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18., PMID:22669586
Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice., PMID:22561312
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers., PMID:22438987
Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice., PMID:22426329
InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers., PMID:22228147
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus., PMID:22069498
Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles., PMID:21803095
Genetic variability in the major capsid L1 protein of human papillomavirus type 16 (HPV-16) and 18 (HPV-18)., PMID:21729769
Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes., PMID:21346798
For research use only. Not for human or drug use.
